(2002). A role for alphasynuclein in the regulation of dopamine biosynthesis.
(2005). Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells.
(2009). Ascherio A
(2005). Atypical cancer pattern in patients with Parkinson’s disease.
(1998). Comparative analysis of the in vivo expression of tyrosinase, MART-1/MelanA, and gp100 in metastatic melanoma lesions: implications for immunotherapy.
(2005). Cutaneous melanoma.
(1999). Detection of microscopic melanoma metastases in sentinel lymph nodes.
(2001). Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma: higher diagnostic accuracy with Melan-A and MART-1 compared with S-100 protein and HMB-45.
(2009). Histopathology report of cutaneous melanoma and sentinel lymph node in Europe: a web-based survey by the Dermatopathology Working Group of the European Society of Pathology.
(2006). Malignant melanoma and other types of cancer preceding Parkinson disease.
(2009). Melanoma biomarkers: current status and vision for the future.
(1999). Melanoma-associated antigen recognized by T cells (MART-1): the advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration.